Aamod S Dekhne,Khushbu Shah,Gregory S Ducker,Jade M Katinas,Jennifer Wong-Roushar,Md Junayed Nayeen,Arpit Doshi,Changwen Ning,Xun Bao,Josephine Frühauf,Jenney Liu,Adrianne Wallace-Povirk,Carrie O'Connor,Sijana H Dzinic,Kathryn White,Juiwanna Kushner,Seongho Kim,Maik Hüttemann,Lisa Polin,Joshua D Rabinowitz,Jing Li,Zhanjun Hou,Charles E Dann,Aleem Gangjee,Larry H Matherly,Aamod S. Dekhne,Gregory S. Ducker,Md. Junayed Nayeen,Joshua D. Rabinowitz,Charles E. Dann

Abstract:Folate-dependent one-carbon (C1) metabolism is compartmentalized into the mitochondria and cytosol and supports cell growth through nucleotide and amino acid biosynthesis. Mitochondrial C1 metabolism, including serine hydroxymethyltransferase (SHMT) 2, provides glycine, NAD(P)H, ATP, and C1 units for cytosolic biosynthetic reactions, and is implicated in the oncogenic phenotype across a wide range of cancers. Whereas multitargeted inhibitors of cytosolic C1 metabolism, such as pemetrexed, are used clinically, there are currently no anticancer drugs that specifically target mitochondrial C1 metabolism. We used molecular modeling to design novel small-molecule pyrrolo[3,2- d ]pyrimidine inhibitors targeting mitochondrial C1 metabolism at SHMT2. In vitro antitumor efficacy was established with the lead compounds ( AGF291 , AGF320 , AGF347 ) toward lung, colon, and pancreatic cancer cells. Intracellular targets were identified by metabolic rescue with glycine and nucleosides, and by targeted metabolomics using a stable isotope tracer, with confirmation by in vitro assays with purified enzymes. In addition to targeting SHMT2, inhibition of the cytosolic purine biosynthetic enzymes, β-glycinamide ribonucleotide formyltransferase and/or 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase, and SHMT1 was also established. AGF347 generated significant in vivo antitumor efficacy with potential for complete responses against both early-stage and upstage MIA PaCa-2 pancreatic tumor xenografts, providing compelling proof-of-concept for therapeutic targeting of SHMT2 and cytosolic C1 enzymes by this series. Our results establish structure–activity relationships and identify exciting new drug prototypes for further development as multitargeted antitumor agents.

Design, synthesis and biological evaluation of novel cyano-cinnamate derivatives as mitochondrial pyruvate carrier inhibitors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Synthesis and biological evaluation of novel pyrazole amides as potent mitochondrial complex I inhibitors

Synthesis, Biological Evaluation and 3D-QSAR Studies of Novel 4,5-Dihydro-1h-pyrazole Niacinamide Derivatives As BRAF Inhibitors

Development of fluoro-7-aminocarboxycoumarin-based mitochondrial pyruvate carrier inhibitors as anticancer agents

Design, Synthesis and Biological Evaluation of Novel and Potent Protein Arginine Methyltransferases 5 Inhibitors for Cancer Therapy

Bioengineering of Hair Follicle-like Structure for Validation of Hair Growth Promoting Compounds

Screening for new inhibitors of the human Mitochondrial Pyruvate Carrier and their effects on hepatic glucose production and diabetes

Design and optimization of novel Tetrahydro-β-carboline-based HDAC inhibitors with potent activities against tumor cell growth and metastasis

Synthesis and Biological Evaluation of Novel N-(piperazin-1-yl)alkyl-1H-dibenzo[a,c]carbazole Derivatives of Dehydroabietic Acid As Potential MEK Inhibitors

Design, Synthesis and Biological Evaluation of (R)-5-methylpyrrolidin-2-ones As P300 Bromodomain Inhibitors with Anti-Tumor Activities in Multiple Tumor Lines.

Design, Synthesis, and Biological Evaluation of Pyrido[2,3- d ]pyrimidin-7(8 H )-one Derivatives As Potent USP1 Inhibitors

Novel Pyrrolo[3,2-d]pyrimidine Compounds Target Mitochondrial and Cytosolic One-carbon Metabolism with Broad-spectrum Antitumor Efficacy

The design, synthesis and biological evaluation of pro-EGCG derivatives as novel anti-vitiligo agents

Activation of the integrated stress response in human hair follicles

A novel and safe small molecule enhances hair follicle regeneration by facilitating metabolic reprogramming

Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma

Novel 4-Acrylamido-quinoline Derivatives As Potent PI3K/mTOR Dual Inhibitors: the Design, Synthesis, and in Vitro and in Vivo Biological Evaluation.

Design and synthesis of novel mitochondria-targeted ergosterol peroxide derivatives as potential anti-cancer agents